Navigation Links
Nucletron Announces 2008 Results
Date:4/24/2009

VEENENDAAL, The Netherlands, April 24 /PRNewswire/ --

- Strong Product Offerings and Leadership in Brachytherapy Contribute to All-Time High

Nucletron, a global leader in radiation oncology, today announced strong financial results in 2008 with net sales of EUR112.4 million (US $165 million). EBITDA in 2008 ended at an all time high (in constant currencies) of EUR17 million with a strong fourth quarter contributing significantly to the year-end success. Despite challenging global economic conditions, Nucletron surpassed projections in 2008 due in large part to a renewed focus on brachytherapy treatment and an expanding product offering in external beam treatment planning software solutions.

Among the several advancements announced in 2008 was the introduction on Oncentra(R) Brachy, a new comprehensive volume-based treatment planning solution that optimizes cancer treatment planning with brachytherapy. Additionally, Oncentra(R) RT Viewer received clearance in 2008. Oncentra RT Viewer enables clinicians to review radiotherapy plans generated with a wide variety of DICOM-compliant treatment planning systems in a Windows (PC) environment.

"In the second half of 2008, we improved our focus on innovation and marketing efforts, while strengthening our management team. Given our many upcoming product releases in the months to come, we are on track to achieve our 2009 goals as planned," said Jos Lamers, chief executive officer of Nucletron.

About Nucletron

Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.


'/>"/>
SOURCE Nucletron B V
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
2. Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
3. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
4. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
5. OmniComm Systems Announces 1st Quarter Results of Operations
6. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
7. China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
8. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
9. Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
10. Metabolex Announces Election of Kurt von Emster to Board of Directors
11. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 According to a report ... derivatives market is fragmented due to the presence of a large pool ... Thermo Fisher , and Sigma-Aldrich, compete with each other in ... collectively, held more than 76% of this market in 2016.  ... As of now, a ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
Breaking Biology Technology:
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
Breaking Biology News(10 mins):